{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:00:10Z","timestamp":1776758410658,"version":"3.51.2"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41375-025-02579-6","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:25:30Z","timestamp":1750911930000},"page":"1915-1927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients"],"prefix":"10.1038","volume":"39","author":[{"given":"Baustin M.","family":"Welch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-8053","authenticated-orcid":false,"given":"Kay L.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"2579_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2579_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. 2017;3:16096.","journal-title":"Nat Rev Dis Prim"},{"key":"2579_CR3","doi-asserted-by":"publisher","first-page":"e2012070","DOI":"10.4084\/mjhid.2012.070","volume":"4","author":"A Nosari","year":"2012","unstructured":"Nosari A. Infectious complications in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2012;4:e2012070.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2579_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","volume":"126","author":"F Forconi","year":"2015","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573\u201381.","journal-title":"Blood"},{"key":"2579_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","volume":"23","author":"VA Morrison","year":"2010","unstructured":"Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pr Res Clin Haematol. 2010;23:145\u201353.","journal-title":"Best Pr Res Clin Haematol"},{"key":"2579_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood.2020006965","volume":"136","author":"AR Mato","year":"2020","unstructured":"Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134\u201343.","journal-title":"Blood"},{"key":"2579_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3390\/ijms21051825","volume":"21","author":"F Arruga","year":"2020","unstructured":"Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020;21:1825.","journal-title":"Int J Mol Sci"},{"key":"2579_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/bjh.15918","volume":"186","author":"S Man","year":"2019","unstructured":"Man S, Henley P. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. Br J Haematol. 2019;186:220\u201333.","journal-title":"Br J Haematol"},{"key":"2579_CR9","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/leu.2014.105","volume":"28","author":"D Saulep-Easton","year":"2014","unstructured":"Saulep-Easton D, Vincent FB, Le Page M, Wei A, Ting SB, Croce CM, et al. Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. Leukemia. 2014;28:2005\u201315.","journal-title":"Leukemia"},{"key":"2579_CR10","first-page":"4497","volume":"63","author":"E Orsini","year":"2003","unstructured":"Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 2003;63:4497\u2013506.","journal-title":"Cancer Res"},{"key":"2579_CR11","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"JC Riches","year":"2013","unstructured":"Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612\u201321.","journal-title":"Blood"},{"key":"2579_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3324\/haematol.2012.073080","volume":"98","author":"M Rossana","year":"2013","unstructured":"Rossana M, Jenny B, Stefania F, Linda B, Silvia M, Carla G, et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 2013;98:1115\u201323.","journal-title":"Haematologica"},{"key":"2579_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41375-018-0280-0","volume":"33","author":"BA Manso","year":"2019","unstructured":"Manso BA, Zhang H, Mikkelson MG, Gwin KA, Secreto CR, Ding W, et al. Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients. Leukemia. 2019;33:638\u201352.","journal-title":"Leukemia"},{"key":"2579_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101994","volume":"24","author":"BA Manso","year":"2021","unstructured":"Manso BA, Krull JE, Gwin KA, Lothert PK, Welch BM, Novak AJ, et al. Chronic lymphocytic leukemia B-cell-derived TNFalpha impairs bone marrow myelopoiesis. iScience. 2021;24:101994.","journal-title":"iScience"},{"key":"2579_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.immuni.2008.08.013","volume":"29","author":"EJ Allenspach","year":"2008","unstructured":"Allenspach EJ, Lemos MP, Porrett PM, Turka LA, Laufer TM. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity. 2008;29:795\u2013806.","journal-title":"Immunity"},{"key":"2579_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, Reis e Sousa C. Dendritic cells revisited. Annu Rev Immunol. 2021;39:131\u201366.","journal-title":"Annu Rev Immunol"},{"key":"2579_CR17","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/nprot.2015.092","volume":"10","author":"G Breton","year":"2015","unstructured":"Breton G, Lee J, Liu K, Nussenzweig MC. Defining human dendritic cell progenitors by multiparametric flow cytometry. Nat Protoc. 2015;10:1407\u201322.","journal-title":"Nat Protoc"},{"key":"2579_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1084\/jem.20141442","volume":"212","author":"J Lee","year":"2015","unstructured":"Lee J, Breton G, Oliveira TYK, Zhou YJ, Aljoufi A, Puhr S, et al. Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. J Exp Med. 2015;212:385\u201399.","journal-title":"J Exp Med"},{"key":"2579_CR19","doi-asserted-by":"publisher","first-page":"e20220867","DOI":"10.1084\/jem.20220867","volume":"221","author":"R Lubin","year":"2024","unstructured":"Lubin R, Patel AA, Mackerodt J, Zhang Y, Gvili R, Mulder K, et al. The lifespan and kinetics of human dendritic cell subsets and their precursors in health and inflammation. J Exp Med. 2024;221:e20220867.","journal-title":"J Exp Med"},{"key":"2579_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nri.2016.116","volume":"17","author":"T Worbs","year":"2017","unstructured":"Worbs T, Hammerschmidt SI, F\u00f6rster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17:30\u201348.","journal-title":"Nat Rev Immunol"},{"key":"2579_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/pharmaceutics12070663","volume":"12","author":"L Amon","year":"2020","unstructured":"Amon L, Hatscher L, Heger L, Dudziak D, Lehmann CHK. Harnessing the complete repertoire of conventional dendritic cell functions for cancer immunotherapy. Pharmaceutics. 2020;12:663.","journal-title":"Pharmaceutics"},{"key":"2579_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432\u201347.","journal-title":"Cell Mol Immunol"},{"key":"2579_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/imm.12252","volume":"142","author":"K Lundberg","year":"2014","unstructured":"Lundberg K, Rydnert F, Greiff L, Lindstedt M. Human blood dendritic cell subsets exhibit discriminative pattern recognition receptor profiles. Immunology. 2014;142:279\u201388.","journal-title":"Immunology"},{"key":"2579_CR24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3389\/fimmu.2019.01014","volume":"10","author":"R Noubade","year":"2019","unstructured":"Noubade R, Majri-Morrison S, Tarbell KV. Beyond cDC1: emerging roles of DC crosstalk in cancer immunity. Front Immunol. 2019;10:1014.","journal-title":"Front Immunol"},{"key":"2579_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fimmu.2015.00363","volume":"6","author":"E Guti\u00e9rrez-Mart\u00ednez","year":"2015","unstructured":"Guti\u00e9rrez-Mart\u00ednez E, Plan\u00e8s R, Anselmi G, Reynolds M, Menezes S, Adiko AC, et al. Cross-presentation of cell-associated antigens by MHC class I in dendritic cell subsets. Front Immunol. 2015;6:363.","journal-title":"Front Immunol"},{"key":"2579_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20100348","volume":"207","author":"A Bachem","year":"2010","unstructured":"Bachem A, G\u00fcttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med. 2010;207:1273\u201381.","journal-title":"J Exp Med"},{"key":"2579_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.20092140","volume":"207","author":"SL Jongbloed","year":"2010","unstructured":"Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207:1247\u201360.","journal-title":"J Exp Med"},{"key":"2579_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41590-020-00824-x","volume":"22","author":"J Canton","year":"2021","unstructured":"Canton J, Blees H, Henry CM, Buck MD, Schulz O, Rogers NC, et al. The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens. Nat Immunol. 2021;22:140\u201353.","journal-title":"Nat Immunol"},{"key":"2579_CR29","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.4049\/jimmunol.1600193","volume":"198","author":"X Yin","year":"2017","unstructured":"Yin X, Yu H, Jin X, Li J, Guo H, Shi Q, et al. Human blood CD1c+ dendritic cells encompass CD5high and CD5low subsets that differ significantly in phenotype, gene expression, and functions. J Immunol. 2017;198:1553\u201364.","journal-title":"J Immunol"},{"key":"2579_CR30","doi-asserted-by":"publisher","first-page":"559166","DOI":"10.3389\/fimmu.2020.559166","volume":"11","author":"L Heger","year":"2020","unstructured":"Heger L, Hofer TP, Bigley V, de Vries IJM, Dalod M, Dudziak D, et al. Subsets of CD1c+ DCs: dendritic cell versus monocyte lineage. Front Immunol. 2020;11:559166.","journal-title":"Front Immunol"},{"key":"2579_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3389\/fimmu.2018.00744","volume":"9","author":"L Heger","year":"2018","unstructured":"Heger L, Balk S, L\u00fchr JJ, Heidkamp GF, Lehmann CHK, Hatscher L, et al. CLEC10A is a specific marker for human CD1c+ dendritic cells and enhances their toll-like receptor 7\/8-induced cytokine secretion. Front Immunol. 2018;9:744.","journal-title":"Front Immunol"},{"key":"2579_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","volume":"50","author":"B Reizis","year":"2019","unstructured":"Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019;50:37\u201350.","journal-title":"Immunity"},{"key":"2579_CR33","doi-asserted-by":"publisher","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","volume":"356","author":"AC Villani","year":"2017","unstructured":"Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356:eaah4573.","journal-title":"Science"},{"key":"2579_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109686","volume":"253","author":"J Kang","year":"2023","unstructured":"Kang J, Kim M, Yoon D-Y, Kim W-S, Choi S-J, Kwon Y-N, et al. AXL+SIGLEC6+ dendritic cells in cerebrospinal fluid and brain tissues of patients with autoimmune inflammatory demyelinating disease of CNS. Clin Immunol. 2023;253. 109686.","journal-title":"Clin Immunol"},{"key":"2579_CR35","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.cell.2007.10.034","volume":"131","author":"CV Rothlin","year":"2007","unstructured":"Rothlin CV, Ghosh S, Zuniga EI, Oldstone MBA, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007;131:1124\u201336.","journal-title":"Cell"},{"key":"2579_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nri2303","volume":"8","author":"G Lemke","year":"2008","unstructured":"Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8:327\u201336.","journal-title":"Nat Rev Immunol"},{"key":"2579_CR37","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.4049\/jimmunol.178.9.5635","volume":"178","author":"HM Seitz","year":"2007","unstructured":"Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different Axl\/Mertk\/Tyro3 receptors in clearance of apoptotic cells. J Immunol. 2007;178:5635\u201342.","journal-title":"J Immunol"},{"key":"2579_CR38","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1016\/j.celrep.2019.11.042","volume":"29","author":"R Leylek","year":"2019","unstructured":"Leylek R, Alc\u00e1ntara-Hern\u00e1ndez M, Lanzar Z, L\u00fcdtke A, Perez OA, Reizis B, et al. Integrated cross-species analysis identifies a conserved transitional dendritic cell population. Cell Rep. 2019;29:3736\u201350.e8.","journal-title":"Cell Rep"},{"key":"2579_CR39","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/s41590-023-01545-7","volume":"24","author":"FB Sulczewski","year":"2023","unstructured":"Sulczewski FB, Maqueda-Alfaro RA, Alc\u00e1ntara-Hern\u00e1ndez M, Perez OA, Saravanan S, Yun TJ, et al. Transitional dendritic cells are distinct from conventional DC2 precursors and mediate proinflammatory antiviral responses. Nat Immunol. 2023;24:1265\u201380.","journal-title":"Nat Immunol"},{"key":"2579_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2010.05.006","volume":"32","author":"M Merad","year":"2010","unstructured":"Merad M. PU.1 takes control of the dendritic cell lineage. Immunity. 2010;32:583\u20135.","journal-title":"Immunity"},{"key":"2579_CR41","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1084\/jem.184.5.1953","volume":"184","author":"E Maraskovsky","year":"1996","unstructured":"Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184:1953\u201362.","journal-title":"J Exp Med"},{"key":"2579_CR42","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/eji.201243163","volume":"43","author":"Y Saito","year":"2013","unstructured":"Saito Y, Boddupalli CS, Borsotti C, Manz MG. Dendritic cell homeostasis is maintained by nonhematopoietic and T-cell-produced Flt3-ligand in steady state and during immune responses. Eur J Immunol. 2013;43:1651\u20138.","journal-title":"Eur J Immunol"},{"key":"2579_CR43","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/imcb.12484","volume":"99","author":"KR Wilson","year":"2021","unstructured":"Wilson KR, Villadangos JA, Mintern JD. Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy. Immunol Cell Biol. 2021;99:962\u201371.","journal-title":"Immunol Cell Biol"},{"key":"2579_CR44","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ni.1615","volume":"9","author":"C Waskow","year":"2008","unstructured":"Waskow C, Liu K, Darrasse-J\u00e8ze G, Guermonprez P, Ginhoux F, Merad M, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008;9:676\u201383.","journal-title":"Nat Immunol"},{"key":"2579_CR45","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3389\/fimmu.2018.01042","volume":"9","author":"R Iwabuchi","year":"2018","unstructured":"Iwabuchi R, Ikeno S, Kobayashi-Ishihara M, Takeyama H, Ato M, Tsunetsugu-Yokota Y, et al. Introduction of human Flt3-L and GM-CSF into humanized mice enhances the reconstitution and maturation of myeloid dendritic cells and the development of Foxp3(+)CD4(+) T cells. Front Immunol. 2018;9:1042.","journal-title":"Front Immunol"},{"key":"2579_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-3606-9_2","volume":"1423","author":"S Balan","year":"2016","unstructured":"Balan S, Dalod M. In vitro generation of human XCR1(+) dendritic cells from CD34(+) hematopoietic progenitors. Methods Mol Biol. 2016;1423:19\u201337.","journal-title":"Methods Mol Biol"},{"key":"2579_CR47","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood.V96.3.878","volume":"96","author":"E Maraskovsky","year":"2000","unstructured":"Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood. 2000;96:878\u201384.","journal-title":"Blood"},{"key":"2579_CR48","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20092618","volume":"207","author":"LF Poulin","year":"2010","unstructured":"Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010;207:1261\u201371.","journal-title":"J Exp Med"},{"key":"2579_CR49","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.cell.2024.04.009","volume":"187","author":"M Momenilandi","year":"2024","unstructured":"Momenilandi M, L\u00e9vy R, Sobrino S, Li J, Lagresle-Peyrou C, Esmaeilzadeh H, et al. FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. Cell. 2024;187:2817\u201337.e31.","journal-title":"Cell"},{"key":"2579_CR50","doi-asserted-by":"publisher","first-page":"1302038","DOI":"10.3389\/fonc.2023.1302038","volume":"13","author":"BM Welch","year":"2023","unstructured":"Welch BM, Manso BA, Gwin KA, Lothert PK, Parikh SA, Kay NE, et al. Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib. Front Oncol. 2023;13:1302038.","journal-title":"Front Oncol"},{"key":"2579_CR51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2023216118","volume":"118","author":"Z Huang","year":"2021","unstructured":"Huang Z, Chen B, Liu X, Li H, Xie L, Gao Y, et al. Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis. Proc Natl Acad Sci USA. 2021;118:e2023216118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2579_CR52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1084\/jem.20011608","volume":"196","author":"GJ Randolph","year":"2002","unstructured":"Randolph GJ, Sanchez-Schmitz G, Liebman RM, Sch\u00e4kel K. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med. 2002;196:517\u201327.","journal-title":"J Exp Med"},{"key":"2579_CR53","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","volume":"56","author":"MJ Pittet","year":"2023","unstructured":"Pittet MJ, Di Pilato M, Garris C, Mempel TR. Dendritic cells as shepherds of T cell immunity in cancer. Immunity. 2023;56:2218\u201330.","journal-title":"Immunity"},{"key":"2579_CR54","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.immuni.2015.07.020","volume":"43","author":"JL Hor","year":"2015","unstructured":"Hor JL, Whitney PG, Zaid A, Brooks AG, Heath WR, Mueller SN. Spatiotemporally distinct interactions with dendritic cell subsets facilitates CD4+ and CD8+ T cell activation to localized viral infection. Immunity. 2015;43:554\u201365.","journal-title":"Immunity"},{"key":"2579_CR55","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.cell.2015.08.004","volume":"162","author":"S Eickhoff","year":"2015","unstructured":"Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, et al. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell. 2015;162:1322\u201337.","journal-title":"Cell"},{"key":"2579_CR56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300343120","volume":"120","author":"L Heger","year":"2023","unstructured":"Heger L, Hatscher L, Liang C, Lehmann CHK, Amon L, L\u00fchr JJ, et al. XCR1 expression distinguishes human conventional dendritic cell type 1 with full effector functions from their immediate precursors. Proc Natl Acad Sci USA. 2023;120:e2300343120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2579_CR57","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1172\/JCI113643","volume":"82","author":"BL Myones","year":"1988","unstructured":"Myones BL, Dalzell JG, Hogg N, Ross GD. Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Investig. 1988;82:640\u201351.","journal-title":"J Clin Investig"},{"key":"2579_CR58","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1073\/pnas.1805542115","volume":"115","author":"J Wu","year":"2018","unstructured":"Wu J, Wu H, An J, Ballantyne CM, Cyster JG. Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. Proc Natl Acad Sci USA. 2018;115:6786\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2579_CR59","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.4049\/jimmunol.152.9.4582","volume":"152","author":"CA Bilsland","year":"1994","unstructured":"Bilsland CA, Diamond MS, Springer TA. The leukocyte integrin p150,95 (CD11c\/CD18) as a receptor for iC3b. Activation by a heterologous beta subunit and localization of a ligand recognition site to the I domain. J Immunol. 1994;152:4582\u20139.","journal-title":"J Immunol"},{"key":"2579_CR60","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","volume":"99","author":"JU Kazi","year":"2019","unstructured":"Kazi JU, R\u00f6nnstrand L. FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications. Physiol Rev. 2019;99:1433\u201366.","journal-title":"Physiol Rev"},{"key":"2579_CR61","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1084\/jem.20030323","volume":"198","author":"H Karsunky","year":"2003","unstructured":"Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med. 2003;198:305\u201313.","journal-title":"J Exp Med"},{"key":"2579_CR62","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/bloodadvances.2019000197","volume":"3","author":"P Milne","year":"2019","unstructured":"Milne P, Wilhelm-Benartzi C, Grunwald MR, Bigley V, Dillon R, Freeman SD, et al. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Adv. 2019;3:3052\u201361.","journal-title":"Blood Adv"},{"key":"2579_CR63","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/35009119","volume":"404","author":"DB Moody","year":"2000","unstructured":"Moody DB, Ulrichs T, M\u00fchlecker W, Young DC, Gurcha SS, Grant E, et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature. 2000;404:884\u20138.","journal-title":"Nature"},{"key":"2579_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10491-8","volume":"10","author":"X Yuan","year":"2019","unstructured":"Yuan X, Qin X, Wang D, Zhang Z, Tang X, Gao X, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients. Nat Commun. 2019;10:2498.","journal-title":"Nat Commun"},{"key":"2579_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38030-6","volume":"14","author":"EN Schmidt","year":"2023","unstructured":"Schmidt EN, Lamprinaki D, McCord KA, Joe M, Sojitra M, Waldow A, et al. Siglec-6 mediates the uptake of extracellular vesicles through a noncanonical glycolipid binding pocket. Nat Commun. 2023;14:2327.","journal-title":"Nat Commun"},{"key":"2579_CR66","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.3390\/cells11213427","volume":"11","author":"AL Stefanski","year":"2022","unstructured":"Stefanski AL, Renecle MD, Kramer A, Sehgal S, Narasimhan P, Rumer KK, et al. Siglec-6 signaling uses Src kinase tyrosine phosphorylation and SHP-2 recruitment. Cells. 2022;11:3427.","journal-title":"Cells"},{"key":"2579_CR67","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1182\/blood-2007-01-066076","volume":"110","author":"B Sargin","year":"2007","unstructured":"Sargin B, Choudhary C, Crosetto N, Schmidt MHH, Grundler R, Rensinghoff M, et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood. 2007;110:1004\u201312.","journal-title":"Blood"},{"key":"2579_CR68","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.1111\/jcmm.15132","volume":"24","author":"F Kellner","year":"2020","unstructured":"Kellner F, Keil A, Schindler K, Tschongov T, H\u00fcnninger K, Loercher H, et al. Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics. J Cell Mol Med. 2020;24:4668\u201376.","journal-title":"J Cell Mol Med"},{"key":"2579_CR69","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood.V88.9.3383.bloodjournal8893383","volume":"88","author":"AM Turner","year":"1996","unstructured":"Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood. 1996;88:3383\u201390.","journal-title":"Blood"},{"key":"2579_CR70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1182\/blood.2020009813","volume":"138","author":"SA Parikh","year":"2021","unstructured":"Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Leis JF, et al. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 2021;138:149\u201359.","journal-title":"Blood"},{"key":"2579_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100930","volume":"54","author":"NE Kay","year":"2022","unstructured":"Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: a continuing evolution in care. Blood Rev. 2022;54:100930.","journal-title":"Blood Rev"},{"key":"2579_CR72","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840\u20137.","journal-title":"Blood"},{"key":"2579_CR73","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","volume":"32","author":"P Bulian","year":"2014","unstructured":"Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, N\u00fcckel H, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol. 2014;32:897\u2013904.","journal-title":"J Clin Oncol"},{"key":"2579_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","volume":"363","author":"JA Orchard","year":"2004","unstructured":"Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105\u201311.","journal-title":"Lancet"},{"key":"2579_CR75","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.15516","volume":"183","author":"M Palma","year":"2018","unstructured":"Palma M, Krstic A, Pe\u00f1a Perez L, Bergl\u00f6f A, Meinke S, Wang Q, et al. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes. Br J Haematol. 2018;183:212\u201324.","journal-title":"Br J Haematol"},{"key":"2579_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106520","volume":"102","author":"IG Solman","year":"2021","unstructured":"Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, et al. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021;102:106520.","journal-title":"Leuk Res"},{"key":"2579_CR77","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142:687\u201399.","journal-title":"Blood"},{"key":"2579_CR78","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323\u201332.","journal-title":"N Engl J Med"},{"key":"2579_CR79","doi-asserted-by":"publisher","first-page":"727531","DOI":"10.3389\/fcell.2021.727531","volume":"9","author":"S Zhu","year":"2021","unstructured":"Zhu S, Gokhale S, Jung J, Spirollari E, Tsai J, Arceo J, et al. Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets\u2014beyond B lymphocytes. Front Cell Dev Biol. 2021;9:727531.","journal-title":"Front Cell Dev Biol"},{"key":"2579_CR80","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","volume":"23","author":"V Patel","year":"2017","unstructured":"Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, et al. Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23:3734\u201343.","journal-title":"Clin Cancer Res"},{"key":"2579_CR81","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1073\/pnas.1513607113","volume":"113","author":"M Kitano","year":"2016","unstructured":"Kitano M, Yamazaki C, Takumi A, Ikeno T, Hemmi H, Takahashi N, et al. Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node. Proc Natl Acad Sci USA. 2016;113:1044\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2579_CR82","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N, Melief CJM, Kastenm\u00fcller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18:635\u201347.","journal-title":"Nat Rev Immunol"},{"key":"2579_CR83","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112\u201320.","journal-title":"Blood"},{"key":"2579_CR84","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1182\/blood.2023022564","volume":"143","author":"P Langerbeins","year":"2024","unstructured":"Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, et al. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies. Blood. 2024;143:2588\u201398.","journal-title":"Blood"},{"key":"2579_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg2752","volume":"379","author":"M He","year":"2023","unstructured":"He M, Roussak K, Ma F, Borcherding N, Garin V, White M, et al. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science. 2023;379:eabg2752.","journal-title":"Science"},{"key":"2579_CR86","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s11864-023-01129-5","volume":"24","author":"S Taghiloo","year":"2023","unstructured":"Taghiloo S, Asgarian-Omran H. Current approaches of immune checkpoint therapy in chronic lymphocytic leukemia. Curr Treat Options Oncol. 2023;24:1408\u201338.","journal-title":"Curr Treat Options Oncol"},{"key":"2579_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686768","volume":"12","author":"M Palma","year":"2021","unstructured":"Palma M, Mulder TA, Osterborg A. BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects. Front Immunol. 2021;12:686768.","journal-title":"Front Immunol"},{"key":"2579_CR88","doi-asserted-by":"crossref","unstructured":"Papazoglou D, Wang V, Shanafelt TD, Lesnick C, Ioannou N, De Rossi G, et al. Ibrutinib-based therapy reinvigorates CD8 T cells compared to chemoimmunotherapy: immune-monitoring from the E1912 trial. Blood. 2024;143:57\u201363.","DOI":"10.1182\/blood.2023020554"},{"key":"2579_CR89","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.4049\/jimmunol.2000742","volume":"205","author":"C Audiger","year":"2020","unstructured":"Audiger C, Lesage S. FLT3 ligand is dispensable for the final stage of type 1 conventional dendritic cell differentiation. J Immunol. 2020;205:2117\u201327.","journal-title":"J Immunol"},{"key":"2579_CR90","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1084\/jem.20091756","volume":"206","author":"F Ginhoux","year":"2009","unstructured":"Ginhoux F, Liu K, Helft J, Bogunovic M, Greter M, Hashimoto D, et al. The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med. 2009;206:3115\u201330.","journal-title":"J Exp Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02579-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T23:51:27Z","timestamp":1757202687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02579-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":90,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2579"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02579-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4953853\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which SAP is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, Genentech, Amgen, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for SAP\u2019s participation in consulting activities\/advisory board meetings. Research funding to NEK has been provided by Acerta Pharma BV, Celgene, Genentech, Pharmacyclics, and Tolero Pharmaceutical. NEK also participates in the data safety monitoring committees of Agios Pharm, AstraZeneca, Celgene, Cytomx Therapeutics, Genentech, Infinity Pharm, Morpho-Sys, and Pharmacyclics (he is not personally compensated for his participation). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}